AngioDynamics Inc (NASDAQ:ANGO) is set to release its Q2 2025 earnings on Jan 8, 2025. The consensus estimate for Q2 2025 revenue is $70.93 million, and the earnings are expected to come in at -$0.22 ...
AngioDynamics, Inc. ANGO recently announced the initiation of a clinical study, AMBITION BTK, comparing the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty with ...
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even ...
The hold thesis remains for AngioDynamics following its latest set of numbers and impeding macro-headwinds. Shares have shown high correlation to long-dated treasury yields in FY22 and this continues ...
Short interest in AngioDynamics Inc (NASDAQ:ANGO) decreased during the last reporting period, falling from 1.70M to 1.49M. This put 4.48% of the company's publicly available shares short. Short ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback